Karen Weintraub is a freelance writer based in Boston, Massachusetts.
Karen Weintraub
Freelance Writer
Simons Foundation/Freelance
From this contributor
Technique follows calcium trail to track changes in signaling
Researchers have genetically engineered neurons to fluoresce in response to the calcium signals emitted when they fire, according to a study published 18 October in Neuron.
Technique follows calcium trail to track changes in signaling
By
Karen Weintraub
24 October 2012 | 2 min read
Researchers uncover new drug target for fragile X
Deleting an enzyme that regulates protein synthesis reverses some of the molecular and behavioral deficits in a mouse model of fragile X syndrome, according to research published 2 October in Neuron.
Researchers uncover new drug target for fragile X
By
Karen Weintraub
4 October 2012 | 5 min read
Drug improves social deficits in fragile X syndrome
A drug called arbaclofen improves behavioral problems in people with fragile X syndrome, an inherited condition that can lead to mental retardation and autism, according to the results of a clinical trial published today in Science Translational Medicine. A second study published in the same journal showed that the drug restores normal brain function in a mouse model of the disorder.
Drug improves social deficits in fragile X syndrome
By
Karen Weintraub
19 September 2012 | 5 min read
Explore more from The Transmitter
Exclusive: The 23 studies the FDA based its expanded leucovorin label on
The studies include 46 people, mostly toddlers, who have cerebral folate deficiency due to variants in a folate transporter.
Exclusive: The 23 studies the FDA based its expanded leucovorin label on
The studies include 46 people, mostly toddlers, who have cerebral folate deficiency due to variants in a folate transporter.
By
Claudia López Lloreda
2 October 2025 | 6 min read
Autism researchers ‘pleasantly surprised’ by list of NIH data project grantees, despite initial concerns
An atypical funding mechanism, truncated application timeline and opaque review process had generated concern over the quality of projects that would be selected for the Autism Data Science Initiative.
Autism researchers ‘pleasantly surprised’ by list of NIH data project grantees, despite initial concerns
An atypical funding mechanism, truncated application timeline and opaque review process had generated concern over the quality of projects that would be selected for the Autism Data Science Initiative.
By
Calli McMurray
2 October 2025 | 10 min read
Exclusive: Who is Richard Frye, the neurologist who researches and advocates for leucovorin as an autism treatment?
Frye has led two placebo-controlled trials of the folate supplement in autistic people; the first was suspended by regulators, and the other has yet to be published.
Exclusive: Who is Richard Frye, the neurologist who researches and advocates for leucovorin as an autism treatment?
Frye has led two placebo-controlled trials of the folate supplement in autistic people; the first was suspended by regulators, and the other has yet to be published.
By
Brendan Borrell
1 October 2025 | 11 min read